Small Lymphocytic Lymphoma — Trials

Small Lymphocytic Lymphoma — Trials · CancerIndex

Clinical trials

Registered studies

479 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 129
Recruiting: 67
Ph III recruiting: 9
Growth YoY: −23.8%
Industry share: 37%
Top sponsor: National Cancer Institute (NCI)
Termination share: 41.2%

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (108)

clinicaltrialsPublishedShowing 1–9 of 9 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT05023980	A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)(BRUIN-CLL-313)	active not recruiting	Phase 3	282	Loxo Oncology, Inc.INDUSTRY	20	Sep 25, 2026	clinicaltrials
NCT02048813	Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma	active not recruiting	Phase 3	529	National Cancer Institute (NCI)